LRMR — Larimar Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374690 ·
Last close
$3.47
Market Cap
$360.47M
52W High
$6.00
52W Low
$3.21
ADV30
1,610,507
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -31,117,000 | -29,613,000 | 208,511,000 | 177,913,000 | 50,478,000 |
| Dec 2025 | 0 | — | -64,018,000 | -62,498,000 | 145,842,000 | 85,412,000 | 67,757,000 |
| Sep 2025 | 0 | — | -49,499,000 | -47,712,000 | 187,350,000 | 90,140,000 | 48,312,000 |
| Jun 2025 | 0 | — | -27,792,000 | -26,182,000 | 149,988,000 | 20,587,000 | 30,134,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-113,201,000
Investing CF
$100,309,000
Financing CF
$65,086,000
CapEx
$-270,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.21
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-434,831,000
Inventory
—
Receivables
$747,000
ST Investments
$51,440,000
EBIT TTM
$-172,497,000
Pretax Income TTM
$-165,673,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,497,000 | -165,673,000 | 145,842,000 | 67,757,000 | — | -113,201,000 |
| Dec 2024 | 0 | -90,890,000 | -80,604,000 | 200,225,000 | 28,413,000 | — | -70,760,000 |
| Dec 2023 | 0 | -41,758,000 | -36,949,000 | 95,935,000 | 14,215,000 | — | -33,459,000 |
| Dec 2022 | 0 | -36,526,000 | -35,355,000 | 126,405,000 | 15,502,000 | — | -27,569,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.25
Max Pain — expiry 2026-08-21
max pain strike: $2.50 · spot: $3.47 · call oi: 9,393 · put oi: 2,833
Expected Move to 2026-08-21:
±$1.90
(54.76%) —
implied range
$1.57 –
$5.37
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | $362.52M | $4.53 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $370.04M | $7.27 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $373.39M | $0.35 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $374.04M | $6.22 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $343.46M | $0.21 | — |
News headlines (Yahoo Finance, 1h cache)
Exploring US High Growth Tech Stocks This May 2026
2026-05-15 11:38 · Yahoo
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
2026-05-14 11:00 · Yahoo
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
2026-04-30 20:05 · Yahoo
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
2026-03-27 07:30 · Yahoo
Larimar: Q4 Earnings Snapshot
2026-03-19 11:22 · Yahoo
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-19 11:00 · Yahoo
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
2026-03-06 15:26 · Yahoo
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
2026-03-04 21:05 · Yahoo
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
2026-03-04 13:50 · Yahoo
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?
2026-02-28 16:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.